WO2004050890A1 - マクロライド系化合物の製造方法 - Google Patents
マクロライド系化合物の製造方法 Download PDFInfo
- Publication number
- WO2004050890A1 WO2004050890A1 PCT/JP2003/015170 JP0315170W WO2004050890A1 WO 2004050890 A1 WO2004050890 A1 WO 2004050890A1 JP 0315170 W JP0315170 W JP 0315170W WO 2004050890 A1 WO2004050890 A1 WO 2004050890A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- ferm
- medium
- substance
- culture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 36
- 239000003120 macrolide antibiotic agent Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 68
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 241000235575 Mortierella Species 0.000 claims abstract description 14
- 241000187747 Streptomyces Species 0.000 claims abstract description 13
- 241001134635 Micromonosporaceae Species 0.000 claims abstract description 12
- 241000187180 Streptomyces sp. Species 0.000 claims abstract description 11
- 210000004748 cultured cell Anatomy 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000011534 incubation Methods 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 241001558147 Mortierella sp. Species 0.000 claims description 12
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- 239000002609 medium Substances 0.000 description 67
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 38
- 229920001817 Agar Polymers 0.000 description 37
- 239000008272 agar Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 29
- 238000011218 seed culture Methods 0.000 description 29
- 239000008103 glucose Substances 0.000 description 28
- 229920002472 Starch Polymers 0.000 description 27
- 235000019698 starch Nutrition 0.000 description 27
- 239000008107 starch Substances 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 26
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 229910000019 calcium carbonate Inorganic materials 0.000 description 19
- 235000010216 calcium carbonate Nutrition 0.000 description 19
- 229940041514 candida albicans extract Drugs 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000012138 yeast extract Substances 0.000 description 19
- 239000001888 Peptone Substances 0.000 description 18
- 108010080698 Peptones Proteins 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 235000019319 peptone Nutrition 0.000 description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 16
- 238000012258 culturing Methods 0.000 description 16
- 235000013372 meat Nutrition 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 108020004463 18S ribosomal RNA Proteins 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 14
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 244000068988 Glycine max Species 0.000 description 12
- 235000010469 Glycine max Nutrition 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 230000000721 bacterilogical effect Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000013587 production medium Substances 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 239000001965 potato dextrose agar Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108010010803 Gelatin Proteins 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 230000001766 physiological effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000020183 skimmed milk Nutrition 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 229910052697 platinum Inorganic materials 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000002689 soil Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 6
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 229920001592 potato starch Polymers 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000005273 aeration Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000000692 cap cell Anatomy 0.000 description 4
- 210000003850 cellular structure Anatomy 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 210000003495 flagella Anatomy 0.000 description 4
- -1 for example Substances 0.000 description 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000015784 hyperosmotic salinity response Effects 0.000 description 4
- 229910017053 inorganic salt Inorganic materials 0.000 description 4
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 4
- 239000000401 methanolic extract Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000006877 oatmeal agar Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000187708 Micromonospora Species 0.000 description 2
- 241000907984 Mortierella hyalina Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241001660006 Verrucosispora Species 0.000 description 2
- 241001660003 Verrucosispora gifhornensis Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710128742 Cytochrome b6-f complex iron-sulfur subunit 2 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241000218939 Micromonospora purpureochromogenes Species 0.000 description 1
- 241001451064 Mortierella chlamydospora Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- DALUDRGQOYMVLD-UHFFFAOYSA-N iron manganese Chemical compound [Mn].[Fe] DALUDRGQOYMVLD-UHFFFAOYSA-N 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
Definitions
- the present invention relates to a method for producing a 12-membered macrolide compound 11107D having antitumor activity by biological conversion and a novel strain used for the method.
- Conventional technology for producing a 12-membered macrolide compound 11107D having antitumor activity by biological conversion and a novel strain used for the method.
- 12-membered ring macrolide compound 11107D is a 12-membered ring macrolide compound with excellent antitumor activity, and was found in a culture of Streptomyces sp. Mer_11107 strain along with 11107B substance (See WO—A 0 2/0 6 0 8 0 9).
- the 11107D substance is equivalent to the 16-position hydroxylated product of the 11107B substance, but its productivity is lower than that of the 11107B substance, and it has been desired to establish an efficient production method. Disclosure of the invention
- An object of the present invention is to provide a novel method for producing a macrolide-based compound 11107D by a biological conversion method using the macrolide-based compound 11107B as a starting material.
- the present inventors have attempted to screen a microorganism capable of converting the hydrogen atom at position 16 of the macrolide compound 11107B into a hydroxyl group from a wide variety of microorganisms to solve the above-mentioned problems.
- Strains belonging to the genus Mortierella, strains belonging to the genus Streptomyces, which are classified as actinomycetes, and strains belonging to the family Micromonosporaceae, which are also classified as actinomycetes Have the above conversion ability, and have completed the present invention.
- the present invention relates to the following (1) to (3).
- (B) a step of collecting the macrolide compound 11107D represented by the formula (II) from the incubation solution obtained in the step (A).
- the strain belonging to the genus Mortierella is Mortierella sp.
- Streptomyces sp. Streptomyces sp. (Streptomyces sp.) AB-1704 strain (FERM BP-8551), A-1544 strain (FERM BP-8446) or A-1545 strain (FERM BP-8447). )).
- Streptomyces sp. AB- having the ability to convert the macrolide compound 11107B represented by the formula (I) into the macrolide compound 11107D represented by the formula ( ⁇ ) 1704 strains (FERM BP-8551).
- Mortierella sp. F-1529 having an ability to convert the macrolide compound 11107B represented by the formula (I) into the macrolide compound 11107D represented by the formula (II). (FERM BP-8547) or F-1530 (FERM
- a microorganism belonging to the genus Mortierella, the genus Streptomyces or the genus Micromonosporaceae which is represented by the above formula (I)
- Any microorganism capable of converting the macrolide compound 11107B substance to the macrolide compound 11107D substance represented by the above formula (II) can be used regardless of the species and strain, but is preferred.
- Mortierella sp. F-1529 strain was obtained from the National Institute of Advanced Industrial Science and Technology Patent Biological Depositary at 1-1, Higashi 1-chome, Tsukuba, Ibaraki, 305-8566 Japan, Japan. Deposited internationally as FERM BP-8547 on January 12, 2012.
- Mortierella sp. F-1530 strain was also obtained from the National Institute of Advanced Industrial Science and Technology (AIST), Patent Organism Depositary, 1-1-1, Higashi, Tsukuba, Ibaraki, 305-8566, Japan, Japan Was deposited internationally as FERM BP-8548 on January 12, 1995.
- Streptomyces sp. AB-1704 strain was obtained from the National Institute of Advanced Industrial Science and Technology, National Institute of Advanced Industrial Science and Technology, Biological Depositary, 1-chome, Tsukuba, Higashi, Ibaraki, 305-8566, Japan. Deposited as FERM P-18999 on September 5, 2015, and 1-1-1, Tsukuba-Higashi, Ibaraki, 305-8566, Japan on January 12, 2003 1 Central Independent Administration at No. 6 It was transferred to the Patent Organism Depositary Center (IP0D) of the National Institute of Advanced Industrial Science and Technology and transferred to the international depository FERM BP-8551.
- IP0D Patent Organism Depositary Center
- A-1544 and A-1545 were also transferred to the Patent Organism Depositary at the National Institute of Advanced Industrial Science and Technology (AIST) at 1-1, Higashi 1-chome, Tsukuba, Ibaraki, 305-8566 Japan, Japan Deposited as FERM P-18943 and FERM P-18944 on July 23, respectively, and 1-1-1, Tsukuba-Higashi, Ibaraki 305-8566, Japan on July 30, 2003 1 Central 6 Were transferred to FERM BP-8446 and FERM BP-8447, international deposits, respectively, at the National Institute of Advanced Industrial Science and Technology Patent Organism Depositary (IP0D).
- IP0D National Institute of Advanced Industrial Science and Technology Patent Organism Depositary
- Oatmeal Agar (hereinafter sometimes abbreviated as OA), Monoretoaga (Malt Agar: 2% Malt extract + 1.5% Agar: hereinafter sometimes abbreviated as MEA), Potato dextrose agar (Potato) Dextrose Agar (hereinafter sometimes abbreviated as PDA)), the colonies show flocose, and the mycelial color is white, exhibiting a white ⁇ -l) color tone. Growth at 25 ° C for 1 week is 75 OA on the OA plate, 75-80 marauders on the MEA plate, and 75-80 marauders on the PDA plate. The mouth has a flower-shape shape. No back coloring and no production of soluble dye is observed. The description of the color tone was based on "Mettune 'Handbook of Color, ethuen Handbook of Color (Kornerup & Wanscher, 1978)".
- Agar plate culture cells of the F-1529 strain were subjected to DNA extraction using FastPrep FP120 (Q-Blogen) and Fast DNA Kit (Q-Blogen).
- PCR was performed using puReTaq Ready-To-Go PCR beads (manufactured by Amersham Biosciences) and PCR primers NS1 and NS8 shown in Tables 1 and 2.
- the PCR product was purified using the QIAquick PCR Purification Kit (QIAGEN) and used for the ABI Prism BigDye Terminator Kit (Applied Biosystems). The sequencer primers are shown in Table 1 and Table 2.
- the resulting 18S rRNA gene of the present strain has the nucleotide sequence of SEQ ID NO: 9. 'DNA base sequences of known strains were obtained from the Japan DMA Data Bank (http: @ ww.ddbj.nig.ac.jp /), and the homology of the 18S rRNA gene was examined. As a result, the 18S rRNA gene of Mortierella hyalina (GenBank, accession no.
- the present inventors have determined that the present strain belongs to the genus Mortierella. ⁇
- the 18S rRNA gene of the F-1530 strain was analyzed in the same manner as for the F-1529 strain.
- the obtained 18S rRNA gene of the F-1530 strain has the nucleotide sequence of SEQ ID NO: 10.
- a DNA base sequence of a known strain was obtained from the Japan DNA Data Bank (http: ⁇ rain.ddbj.nig.ac.jp /), and the homology of the 18S rRNA gene was examined.
- the 18S rRNA gene of Mortierella hyalina (GenBank, accession no.AY157493) and 100% (803 bases upstream)
- the 18S rRNA gene of Mortierella chlamydospora (GenBank, accession no. It showed 98% (full length) homology with the 18S rRNA gene of GenBank, accession no. AF157144).
- this strain belongs to the genus Mortierella.
- aerial hyphae Extends aerial hyphae (Rectiflexibiles type) from the base hyphae. It forms a spore chain consisting of about 20 to 50 cylindrical spores at the tip of a mature aerial hypha. The size of the spore is 0.6-0.8, 1.0-1.111. The surface of the spore is smooth, and special organs such as spore sac, sclerotium, and flagella are unacceptable.
- Table 3 shows the culture characteristics after culturing at 28 ° C for about 2 weeks on various media.
- the description of the color tone is indicated by the color name of Tresner's color wheel (Tresner's Color wheels) and the code shown in parentheses.
- Table 4 shows the growth after 2 weeks of culture at 28 ° C with various carbon sources added to Prideham-Gottrie agar medium.
- the present inventors have determined that the present strain belongs to the genus Streptomyces.
- Spira type aerial hyphae extend from the base hyphae.
- a spore chain consisting of about 10 to 20 cylindrical spores is formed at the tip of a mature aerial hypha.
- the size of spores is 1.0 X 1.2 to 1.4 ⁇ , and the surface of spores is spiny, and there are no special organs such as spores, sclerotium, and flagella. .
- Table 5 shows the culture properties after culturing on various media at 28 ° C for about 2 weeks. The description of the color tone is indicated by the color mark of Tresner's Color Wheels and the code in parentheses.
- Table 6 shows the growth status after adding varieties of carbon sources to Preedham Gottling agar medium and culturing at 28 ° C for 2 weeks.
- Salt tolerance (yeast / malt agar medium, cultured for 2 weeks): Grow at a salt content of 7% or less
- the present inventors have determined that the present strain belongs to the genus Streptomyces.
- the size of the spores is about 0.8 ⁇ 1.0 ⁇ m, and the surface of the spores is smooth, and there are no special organs such as spores, sclerotium, and flagella.
- Table 7 shows the culture properties after culturing at 28 ° C for about 2 weeks on various media.
- the color notation is indicated by the color name of Tresner's color wheels and the sign in parentheses.
- Table 8 shows the growth after 2 weeks of cultivation at 28 ° C with various carbon sources added to the Preedham-Gottrie agar medium.
- the present inventors have determined that the present strain belongs to the genus Streptomyces.
- the AB-1896 strain shows good or moderate growth in culture at 28 ° C for 7 to 14 days on the medium used for strain identification. ⁇ ⁇ No aerial hyphae were observed during cultivation, and spores were observed one by one on the basal hyphae. The spores are spherical, about 0.8-0.9 ⁇ in size, and the spores are warty on the surface. No special organs such as sporangia, sclerotium, and flagella are found.
- Table 9 shows the culture characteristics after culturing on various media at 28 ° C for about 2 weeks.
- the description of the color tone is indicated by the name of the color wheel of Tresner's color wheels and the code shown in parentheses. .
- Table 10 shows the growth status after 2 weeks of culture at 28 ° C with various carbon sources added to Preed Ham's Gottling agar medium.
- Meso-type diaminopimelic acid was detected from the cell wall of AB-1896 strain. Xylose and mannose were detected as major constituent sugars of all cells. The acyl type in the cell wall peptide glycan was glycolyl type. Mycolic acid was not detected. Major Menakino in as component MK- 9 (H 4), MK- 9 (H 6), MK- 10 (H 4), MK- 10 (H 6) were detected.
- Purification was performed using Purification Kit (manufactured by QIAGEN) and used as a sample for sequencing.
- Sequencing was performed according to a standard protocol using an ABI PRISM 310 Genetic Analyzer (manufactured by Applied Biosystems) and a BigDye Terminator kit.
- the primer used was 9F, 536R.
- a DNA base sequence of a known strain was obtained from the Japan DNA Data Bank (http: ⁇ www.ddbj.nig.ac.jp /), and the homology between the 400-500 bases at the 5 'end of the 16s rRNA gene was examined. .
- 98% of the 16s rRNA Jodenna of the micro image ospora sp.DSM44396 GenBank, accession no.AJ560637
- 98% of the Micromonospora purpureochromogenes GenBank, accession no. -3 genera reference strain !!
- AB-1896 strain is not completely identical to the genus Micromonospora in that arabinose was not detected as a major constituent sugar of all the cells and mannose was detected, which is characteristic of the genus Micromonospora.
- the characteristic spores found in Verrucosispora gifhornensis are not observed on the medium used for strain identification, and thus do not completely match the genus Verrucosispora.
- the present inventors determined that the AB 1896 strain was an actinomycete belonging to the Family Micromonosporaceae in consideration of these mycological properties comprehensively.
- a macrolide-based compound 11107B substance as a starting material is incubated in the presence of the above-mentioned strain or a cultured cell preparation thereof, and oxygen.
- This treatment is carried out by adding a substrate to the culture solution when culturing the strain under aerobic conditions, or, if necessary, by preparing a cultured cell of the strain, for example, as it is or homogenized.
- the suspension may be added with a substrate, and incubated with aeration containing an oxygen-containing gas, for example, air.
- the substrate may be added to the culture solution at any time before the culturing or when a certain period of time has elapsed after the start of the culturing.
- the cells can be produced by inoculating any of the above strains into a nutrient-containing medium and aerobically culturing them.
- the culturing of the strain for preparing the preparation of such cultured cells or the culturing of the strain with the substrate added thereto can be performed in principle according to a general microorganism culturing method. It is preferable to carry out the culture under aerobic conditions such as shaking culture by liquid culture and aeration and stirring culture.
- the medium used for the culture may be any medium containing a nutrient source that can be used by microorganisms belonging to the genus Mortierella, the genus Streptomyces, or the genus Micromonosporaceae. Any synthetic medium, semi-synthetic medium, natural medium, etc. can be used.
- the composition of the medium is as a carbon source, such as gnorecose, galactose, sucrose, manolethose, phenol, glycerin, dextrin, starch, Molasses, soybean oil, etc. can be used alone or in combination.
- Nitrogen sources include pharmamedia, peptone, meat extract, soybean meal, fishmeal, gluten meal, casein, dried yeast, amino acids, yeast extract, NZ-case, organic nitrogen sources such as urea, sodium nitrate, and ammonium sulfate.
- organic nitrogen sources such as urea, sodium nitrate, and ammonium sulfate.
- Inorganic nitrogen sources such as platinum can be used alone or in combination.
- salts such as sodium salt sodium, potassium chloride, calcium carbonate, magnesium sulfate, sodium phosphate, potassium phosphate, copper sulfate, iron sulfate, ⁇ iron salt manganese, salts such as cobalt chloride, salts of heavy metals, vitamin B
- clathrates such as vitamins such as biotin, and dextrins at the mouth can also be used. If foaming during culturing is remarkable, various antifoaming agents can be appropriately added to the medium. When adding antifoam, it is necessary to use a concentration that does not adversely affect the production of the target substance.
- Cultivation conditions can be appropriately selected within a range in which the strain can grow well and produce the above-mentioned substance.
- the pH of the medium is preferably about 5 to 9, usually around neutral.
- the culture temperature is generally maintained at 20 to 40 ° C, preferably at 24 to 30 ° C.
- the culture period is about 1 to 8 days, usually about 2 to 5 days.
- a cultured cell preparation is prepared by suspending the cells isolated by centrifugation or filtration or homogenized cells in an appropriate solution after the completion of the culture.
- the solution that can be used for suspending the cells is the above-described medium, or a buffer solution such as tris-acetic acid, tris-hydrochloric acid, sodium succinate, sodium citrate, sodium phosphate, or potassium phosphate alone or mixed. Things.
- the pH of the buffer is between 5.0 and 9.0, preferably between 6.0 and 7.5.
- the substrate 11107B substance can be added to the culture solution or cell suspension, either as a powder or dissolved in a water-soluble organic solvent such as ethanol, methanol, acetone or dimethyl sulfoxide.
- a water-soluble organic solvent such as ethanol, methanol, acetone or dimethyl sulfoxide.
- the addition amount is preferably 50 to 5000 mg per 1 L of the culture solution.
- shaking or aeration and agitation are performed at 20-31 ° C for about 1-5 days, and the reaction is allowed to proceed under aerobic conditions to convert the 11107B substance as the target Can be converted into a substance.
- the incubation treatment obtained in the step (A) is performed.
- the isolation of the 11107D substance from the reaction mixture of step (A) can be carried out by selecting and combining various known purification techniques generally used for isolating microbial metabolites. For example, organic solvent extraction using methanol, ethanol, ptanol, acetone, ethyl acetate, butyl acetate, chloroform, toluene, etc., various ion exchange chromatography, gel filtration using Sephadex LH-20, etc.
- hydrophobic adsorption resin such as Diaion HP-20, adsorption chromatography using activated carbon, silica gel, etc., adsorption / desorption treatment using thin-layer chromatography, or high-performance liquid chromatography using a reversed-phase column, etc.
- 0.1 ml of this culture was inoculated into a 500 ml Erlenmeyer flask containing 100 ml of the same seed culture medium, and cultured at 28 ° C. for 1 day to obtain a second stage seed culture.
- 800 ml of the second-stage seed culture obtained in this manner was mixed with a production medium (soluble starch 5.0%, formalmedia 0.8%, gluten meal 0.8%, yeast extract 0.5%, calcium carbonate 0.
- the column was eluted with a mixture (2 L) of n-hexane and ethyl acetate (l: 9; v / v). The fractions eluted from 468 ml to 1260 ml were collected and concentrated under reduced pressure. 25 mg of a crude active fraction was obtained.
- the crude active fraction obtained was subjected to preparative high performance liquid chromatography under the following HPLC preparative conditions (A) — (HPLC), and the fraction eluted at a retention time of 34 minutes was collected, and acetonitrile was distilled off. Thereafter, the fraction was subjected to desalting by HPLC under the following HPLC preparative conditions (B) to obtain 6 mg of 11107B substance (retention time: 37 minutes).
- Slope culture of bacterial strain isolated from soil [Soluble starch 0.5%, glucose 0.5%, fish meat ⁇ kiss (manufactured by Wako Pure Chemical Industries, Ltd.) 0.1%, yeast extract (Oriental Yeast Co., Ltd.) 0.1% NZ-case (manufactured by Humco 'Sheffield' Chemical) 0.2%, sodium chloride 0.2%, calcium carbonate 0.1%, agar (manufactured by Wako Pure Chemical Industries, Ltd.) 1.6%] to 1 ml of seed culture medium [soluble starch 2.0%, glucose 1.0%, polypeptone (Nippon Pharmaceutical Co., Ltd.) 0.5%, yeast extract (Oriental yeast) (Industrial Co., Ltd.) 0.5%, calcium carbonate 0.1%] was inoculated into a 65 ml test tube, and cultured at 28 ° C for 3 days on a shaking incubator for seed culture. A liquid was obtained.
- 0.5 ml of the seed culture medium was added to 7 ml of a production medium [soluble starch 2.0%, glucose 1.0%, polypeptone (Nippon Pharmaceutical Co., Ltd.) 0.5%, yeast extract (Oriental Yeast Co., Ltd.) 0.5%, calcium carbonate 0.1%] in 65 ml test tubes, and cultured on a shaking incubator at 28 ° C for 3 days.
- 11107B substance as a substrate was prepared as a 25 mg / ml ethanol solution, and 0.2 ml was added. After the addition, the mixture was shaken at 28 ° C for 48 hours to perform a conversion reaction. After the reaction, HPLC analysis was performed under the following HPLC analysis conditions (a) to obtain a strain in which 11107D substance was generated in the reaction mixture, strain AB-1704 (FERM BP-8551).
- 0.6 ml of the seed culture was added to 60 ml of a production medium [soluble starch 2.0%, glucose 2.0 ° / 0 , soybean powder (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, yeast ⁇ kis (Oriental) 0.5%, sodium chloride 0.25%, calcium carbonate 0.32%, copper sulfate 0.0005%, manganese chloride 0.0005%, zinc sulfate 0.0005%, before sterilization
- the cells were subcultured in a 500 ml Erlenmeyer flask containing ⁇ 7.4] and cultured on a shaking incubator at 28 ° C for 4 days. 2 ml of the resulting culture was dispensed into 15 ml test tubes.
- the substance 11107B as a substrate was prepared as a 20 mg / ml dimethyl sulfoxide solution, and 0.05 ml ′ was added. After the addition, the mixture was shaken at 28 ° C for 23 hours to perform a conversion reaction. After the reaction, HPLC analysis was performed under the following HPLC analysis conditions (b), and the strain in which the 11107D substance was generated in the reaction mixture, the A-1544 strain (FERM BP-8446) and the A-1545 strain (FERM BP-8447) ).
- Slope medium of Streptomyces sp. AB-1704 strain (FERM BP-8551) isolated from soil [Soluble starch 0.5%, glucose 5%, fish meat extract (manufactured by Wako Pure Chemical Industries, Ltd.) 0.1%, yeast extract (manufactured by Oriental Yeast Co., Ltd.) 0.1%, ⁇ -case (manufactured by Fumco Sheffield Chemical Co.) 0.2%, sodium chloride 0.2%, calcium carbonate 0.1 %, Agar (produced by Wako Pure Chemical Industries, Ltd., 1.6%) and a loop of 100 ml of seed medium [soluble starch 2.0%, glucose 1.0%, polypeptone (produced by Nippon Pharmaceutical Co., Ltd.) ) 0.5%, yeast extract (manufactured by Oriental Yeast Co., Ltd.) 0.5%, calcium carbonate 0.1%] inoculated into a 500 ml Erlenmeyer flask, and shake culture at 28 ° C for 3 days The seed culture was obtained by cult
- the obtained ethyl acetate solution was concentrated under reduced pressure to obtain 2090 mg of a crude active fraction.
- This crude active fraction was dissolved in 4 ml of a mixture of tetrahydrofuran-methanol (1: 1, v / v) and 6 ml of a 50% aqueous solution of acetonitrile, and subjected to 0DS column chromatography (0DS-A120- S50 3.6 cm X 43 cm) and eluted with 40% aqueous acetonitrile.
- the fraction eluted from 336 ml to 408 ml was concentrated to dryness under reduced pressure to obtain 560 mg of a residue.
- the residue was further dissolved in 10 ml of a 50% aqueous methanol solution, subjected to 0DS-force chromatograph (ODS-AM120-S50, ⁇ 3.6 cm ⁇ 40 cm, manufactured by IEMS Corporation), and eluted with a 50% aqueous methanol solution.
- ODS-AM120-S50 ⁇ 3.6 cm ⁇ 40 cm, manufactured by IEMS Corporation
- the fraction eluted from 1344 ml to 182-1 was concentrated to dryness under reduced pressure to obtain 252 mg of 11107D substance.
- a loop of 25 ml of seed culture medium [Soluble starch 2.0%, glucose 2.0%, soybean flour (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, Yeast extract (Dco) 0.5%, Sodium chloride 0.25%, Calcium carbonate 0.32%, 250ml with ⁇ 7.4 before sterilization]
- the inoculated Erlenmeyer flask was cultured at 28 ° C. for 2 days on a shaking incubator to obtain a seed culture. 0.75 ml of this culture solution was dispensed into a 2-ml serum tube (manufactured by Sumitomo Bakelite Co., Ltd.), and the same volume of a 40% glycerol aqueous solution was added thereto.
- Seed mothers were made. This frozen seed mother was thawed, and 0.25 ml of the medium was dissolved in 25 ml of seed mother medium [soluble starch 2.0%, glucose 2.0%, soybean flour (Essan Meat, Ajinomoto Co., Ltd.) 2.0% , Yeast extract (Oriental Yeast Industry 0.5%, 0.25% sodium chloride, 0.32% calcium carbonate, pre-sterilization ⁇ 7.4] inoculated into a 250 ml Erlenmeyer flask and shaken at 28 ° C for 2 days A seed culture was obtained by culturing on an incubator.
- seed mother medium soluble starch 2.0%, glucose 2.0%, soybean flour (Essan Meat, Ajinomoto Co., Ltd.) 2.0% , Yeast extract (Oriental Yeast Industry 0.5%, 0.25% sodium chloride, 0.32% calcium carbonate, pre-sterilization ⁇ 7.4] inoculated into a 250 ml Erlenmeyer flas
- seed culture was added to 100 ml of a production medium [soluble starch 2.0%, glucose 2.0%, soybean powder (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, yeast extract (Oriental yeast) (Manufactured by Kogyo Co., Ltd.) 0.5%, 0.25% sodium chloride, 0.32% calcium carbonate, pH 7.4 prior to sterilization. Transfer to a 500 ml Erlenmeyer flask and shake at 28 ° C for 3 days. The cells were cultured on a tomato incubator.
- the resulting cultures (100 ml / 500 ml Erlenmeyer flasks, 10 tubes) were each centrifuged at 3000 rpm for 10 minutes to collect the cells, and suspended in 100 ml of 50 mM phosphate buffer (pH 6.0).
- 11107B substance as a substrate was prepared as a 100 mg / ml dimethyl sulfoxide solution, and each was added to the solution. After the addition, the mixture was shaken at 28 ° C for 24 hours to perform a conversion reaction. After completion of the reaction, the reaction solution was collected and separated into a supernatant and bacterial cells by centrifugation at 5000 rpm for 20 minutes. The supernatant was extracted with 1 L of ethyl acetate.
- the cells were extracted with 500 ml of methanol and filtered to obtain a methanol extract. After methanol was distilled off from the methanol extract under reduced pressure, the mixture was extracted with 1 L of ethyl acetate. The respective ethyl acetate layers were washed with water, dehydrated and dried over anhydrous sodium sulfate, and then combined under reduced pressure to obtain 937 mg of a crude fraction.
- the cells were extracted with 500 ml of acetone and filtered to obtain an acetone extract. After acetone was distilled off from the acetone extract under reduced pressure, the mixture was extracted with 1 L of ethyl acetate. Each ethyl acetate layer was washed with water, dehydrated and dried over anhydrous sodium sulfate, and then combined and concentrated under reduced pressure to obtain 945 mg of a crude fraction.
- This crude fraction was subjected to silica gel column chromatography (Kiesel gel 60, 50 g), and a mixture of ethyl acetate and ⁇ -hexane (50:50; v / v) (100 ml), ethyl acetate and n-hexane (75 : 25; v / v) and a mixture of ethyl acetate and n-hexane (90:10; v / v) (600 ml) to obtain 463 mg of a fraction containing 11107D substance.
- the obtained fraction was subjected to preparative high-performance liquid chromatography (HPLC) under the preparative conditions (C) described in Example 4, and the obtained eluate was subjected to HPLC under the analytical conditions (c) described in Example 4. analyzed.
- HPLC preparative high-performance liquid chromatography
- the solvent was distilled off from the thus obtained fraction containing the 11107D substance to obtain 304 mg of the 11107D substance.
- slant medium potato dextrose agar medium
- a slant medium potato dextrose agar medium
- a 20 ml seed mother medium potato starch 2.0%, glucose 1.0%, soybean powder (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, monopotassium phosphate 0.1%, magnesium sulfate heptahydrate (0.05%) was inoculated into a 250 ml Erlenmeyer flask, and cultured on a shaking incubator at 25 ° C for 3 days to obtain a seed culture.
- 0.6 ml of the seed culture was added to 60 ml of a production medium (potato starch 2.0%, glucose 1.0%, soybean flour (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, phosphoric acid reaper 0 (1%, 0.05% magnesium sulfate heptahydrate) in a 500-ml triangular flask, and cultured at 28 ° C for 4 days on a shaking incubator. 2 ml of the obtained culture was dispensed into 15 ml test tubes. Each was harvested by centrifugation at 3000 rpm for 5 minutes and suspended in 2 ml of 50 mM phosphate buffer (pH 7.0).
- a production medium potato starch 2.0%, glucose 1.0%, soybean flour (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, phosphoric acid reaper 0 (1%, 0.05% magnesium sulfate heptahydrate
- 11107B substance as a substrate was prepared as a 20 tng / ml dimethyl sulfoxide solution, and 0.05 ml of each was added. After the addition, the mixture was shaken at 28 ° C for 23 hours to carry out a hydroxylation reaction. After the reaction, HPLC analysis was carried out under the analysis conditions (c) described in Example 4. The strain showing the peak of the 11107D substance, strain F-1529 (FERM BP8547) and strain F-1530 (FERM BP-8548) I got
- 0.6 ml of the seed culture medium to 60 ml of a production medium [potato starch 2.0%, glucose 1.0%, soybean powder (Essan Meat, Ajinomoto Co.) 2.0%, monopotassium phosphate 0.1%, magnesium sulfate heptahydrate (0.05%) in a 500 ml Erlenmeyer flask, and cultured on a shaking incubator at 25 ° C for 3 days.
- the obtained cultures (18 ml of 60 ml / 500 ml Erlenmeyer flasks) were collected by centrifugation at 3000 rpm for 5 minutes, and suspended in 60 ml of 50 mM phosphate buffer (pH 7.0).
- 11107B substance as a substrate was prepared as a 100 mg / ml dimethyl sulfoxide solution, and 0.6 ml of each was added. After the addition, the mixture was shaken at 25 ° C for 22 hours to perform a conversion reaction. After the completion of the reaction, the filtrate and the cells were separated by centrifugation at 5000 rpm for 20 minutes. The supernatant was extracted with 1 L of ethyl acetate.
- the cells were extracted with 500 ml of acetone and filtered to obtain an acetone extract. After distilling off acetone from the acetone extract under reduced pressure, 1 L of acetate Extracted with chill. Each ethyl acetate layer was washed with water, dehydrated and dried over anhydrous sodium sulfate, and then combined under reduced pressure to obtain 1.21 g of a crude fraction containing 11107D substance. The crude fraction containing the 11107D substance was subjected to silica gel column chromatography (Kiesel gel 60, 50 g), and eluted with 1200 ml of a mixture of ethyl acetate and n-hexane (90:10; v / v). A fraction containing 369 mg was obtained.
- the obtained fraction was subjected to preparative high-performance liquid chromatography (HPLC) under the HPLC preparative conditions (C) described in Example 4 to obtain a fraction containing the eluted 11107D substance. By distilling off the solvent, 180 mg of 11107D substance was obtained.
- HPLC high-performance liquid chromatography
- 0.6 ml of the seed culture was added to 60 ml of the production medium [potato starch 2.0%, glucose 1.0%, soybean powder (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, monopotassium phosphate 0% .1%, magnesium sulfate heptahydrate (0.05%) in a 500 ml Erlenmeyer flask, and cultured on a shaking incubator at 25 ° C for 3 days.
- the production medium potato starch 2.0%, glucose 1.0%, soybean powder (Essan Meat, Ajinomoto Co., Ltd.) 2.0%, monopotassium phosphate 0% .1%, magnesium sulfate heptahydrate (0.05%) in a 500 ml Erlenmeyer flask, and cultured on a shaking incubator at 25 ° C for 3 days.
- the obtained culture solution (18 ml of a 60 ml / 500 ml Erlenmeyer flask) was harvested by centrifugation at 3000 rpm for 5 minutes, and suspended in 60 ml of a 50 mM phosphate buffer (pH 7.0).
- a substance, 11107B was prepared as a 100 mg / ml dimethyl sulfoxide solution, and 0.6 ml of each was added. After the addition, the mixture was shaken at 25 ° C for 22 hours to perform a conversion reaction. After the completion of the reaction, the filtrate and the cells were separated by centrifugation at 5000 rpm for 20 minutes. The supernatant was extracted with 1 L of ethyl acetate.
- the cells were extracted with 500 ml of acetone and filtered to obtain an acetone extract. After acetone was distilled off from the acetone extract under reduced pressure, the mixture was extracted with 1 L of ethyl acetate. Each ethyl acetate layer was washed with water, dehydrated and dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a crude fraction of 0.89 g containing the substance 11107D.
- the crude fraction containing the 11107D substance is subjected to silica gel column chromatography (Kiesel gel 60, 50 g) and eluted with 1200 ml of a mixture of ethyl acetate and n-hexane (90:10; v / v), and then 500 ml of ethyl acetate to obtain 163 mg of a crude fraction containing 11107D substance.
- the obtained fraction was subjected to preparative high-performance liquid chromatography (HPLC) under the HPLC preparative conditions (C) described in Example 4 to obtain a fraction containing the eluted 11107D substance. By distilling off, 30 mg of 11107D substance was obtained.
- AB-1896 strain medium soluble starch 0.5%, glucose 0.5%, fish meat extract (manufactured by Wako Pure Chemical Industries, Ltd.) 0.1 ° yeast extract (manufactured by Oriental Yeast Co., Ltd.) 0 1%, NZ-case (manufactured by Humco's Sheffield Chemical) 0.2%, sodium chloride 0.2%, carbonated calcium 0.1%, agar (manufactured by Wako Pure Chemical Industries, Ltd.) 1 6%) to 5 ml of seed culture medium (soluble starch 2.0%, glucose 1.0%, polypeptone (Nippon Pharmaceutical Co., Ltd.) 0.5%, yeast extract (Oriental Yeast Co., Ltd.
- 0.5%, 0.1% calcium carbonate was inoculated into a 65 ml test tube and cultured on a shaking incubator at 28 ° C for 10 days to obtain a seed culture. .
- 0.1 ml of seed culture was added to 5 ml of production medium (soluble starch 2.0%, glucose 1.0%, polypeptone (Nippon Pharmaceutical Co., Ltd.) 0.5%, yeast extract (Oriental Yeast Kogyo Co., Ltd.) (0.5%, calcium carbonate 0.1%) in a 65 ml test tube, and cultured on a shaking incubator at 28 ° C for 3 days.
- the substrate, 11107B substance was prepared as a 40 mg / ml ethanol solution in the obtained culture solution (5 ml / 65 ml test tube, 1 tube), and was added to 0.05 ⁇ 0. After the addition, the mixture was shaken at 28 ° C for 24 hours to carry out a hydroxylation reaction. The resulting culture solution was collected 3ml fraction, after shaking by adding 2ml of 1-butanol and centrifuged 10 minutes at 3000 r P m. The obtained supernatant was distilled off, and a 2 ml methanol solution was subjected to HPLC analysis under the following HPLC analysis conditions (e) and (f), and 11107D substance was generated in the reaction mixture. It was confirmed.
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03775924A EP1580278A4 (en) | 2002-11-29 | 2003-11-27 | METHOD FOR PRODUCING A MAKROLIDE COMPOUND |
US10/532,412 US7745198B2 (en) | 2002-11-29 | 2003-11-27 | Method of producing macrolide compound |
JP2004556846A JP4439401B2 (ja) | 2002-11-29 | 2003-11-27 | マクロライド系化合物の製造方法 |
AU2003284469A AU2003284469B2 (en) | 2002-11-29 | 2003-11-27 | Process for producing macrolide compound |
BR0316746-1A BR0316746A (pt) | 2002-11-29 | 2003-11-27 | Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) |
MXPA05005672A MXPA05005672A (es) | 2002-11-29 | 2003-11-27 | Metodo para producir un compuesto a macrolido. |
CA002507641A CA2507641A1 (en) | 2002-11-29 | 2003-11-27 | Method of producing macrolide compound |
NZ540103A NZ540103A (en) | 2002-11-29 | 2003-11-27 | Process for producing macrolide compound |
NO20052568A NO20052568L (no) | 2002-11-29 | 2005-05-27 | Fremgangsmate for fremstilling av makrolidforbindelse |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002346796 | 2002-11-29 | ||
JP2002-346796 | 2002-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004050890A1 true WO2004050890A1 (ja) | 2004-06-17 |
Family
ID=32462862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015170 WO2004050890A1 (ja) | 2002-11-29 | 2003-11-27 | マクロライド系化合物の製造方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7745198B2 (ja) |
EP (1) | EP1580278A4 (ja) |
JP (1) | JP4439401B2 (ja) |
KR (1) | KR20050086873A (ja) |
CN (1) | CN1717493A (ja) |
AU (1) | AU2003284469B2 (ja) |
BR (1) | BR0316746A (ja) |
CA (1) | CA2507641A1 (ja) |
MX (1) | MXPA05005672A (ja) |
NO (1) | NO20052568L (ja) |
NZ (1) | NZ540103A (ja) |
RU (1) | RU2330069C2 (ja) |
WO (1) | WO2004050890A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052152A1 (ja) * | 2003-11-27 | 2005-06-09 | Mercian Corporation | マクロライド系化合物の水酸化に関与するdna |
WO2006126723A1 (ja) * | 2005-05-26 | 2006-11-30 | Eisai R & D Management Co., Ltd. | 遺伝子組換え微生物およびそれらの微生物を用いるマクロライド系化合物の製造方法 |
EP1770165A1 (en) * | 2004-07-20 | 2007-04-04 | Eisai R&D Management Co., Ltd. | Dna coding for polypeptide participating in biosynthesis of pladienolide |
WO2007043621A1 (ja) * | 2005-10-13 | 2007-04-19 | Eisai R & D Management Co., Ltd. | プラジエノライド b及びプラジエノライド dの全合成方法 |
WO2015175594A1 (en) | 2014-05-15 | 2015-11-19 | Eisai R&D Management Co., Ltd. | Pladienolide pyridine compounds and methods of use |
WO2017040526A2 (en) | 2015-09-01 | 2017-03-09 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
WO2017087667A1 (en) | 2015-11-18 | 2017-05-26 | Eisai R&D Management Co., Ltd. | A solid state form of pladienolide pyridine compounds and methods of use |
WO2018170129A1 (en) | 2017-03-15 | 2018-09-20 | Eisai Co., Ltd | Spliceosome mutations and uses thereof |
WO2019089641A1 (en) | 2017-10-31 | 2019-05-09 | Eisai R&D Management Co., Ltd. | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use |
WO2019200100A1 (en) | 2018-04-12 | 2019-10-17 | Andrew Cook | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
WO2019199667A2 (en) | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
WO2019232433A2 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
WO2022098712A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI334866B (en) * | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
EP2052723A4 (en) * | 2006-08-14 | 2010-07-28 | Eisai R&D Man Co Ltd | STABLE LYOPHILIZED PREPARATION |
CN101616912A (zh) * | 2007-01-29 | 2009-12-30 | 卫材R&D管理有限公司 | 大环内酯系化合物的固体及其制造方法及其药物组合物 |
CA3130061A1 (en) | 2013-04-04 | 2014-10-09 | President And Fellows Of Harvard College | Macrolides and methods of their preparation and use |
JP2017531663A (ja) * | 2014-10-08 | 2017-10-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 14員ケトライドならびにそれらの調製および使用の方法 |
CA2980315A1 (en) | 2015-03-25 | 2016-09-29 | President And Fellows Of Harvard College | Macrolides with modified desosamine sugars and uses thereof |
CN114478257A (zh) * | 2021-12-29 | 2022-05-13 | 福建省山河药业有限公司 | 一种抗肿瘤霉菌酸类化合物及其制备方法、应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04352783A (ja) * | 1991-05-27 | 1992-12-07 | Taisho Pharmaceut Co Ltd | 12員環マクロライド系化合物 |
WO2002060890A1 (fr) * | 2001-02-01 | 2002-08-08 | Mercian Corporation | Nouvelles substances physiologiquement actives |
WO2003099813A1 (fr) * | 2002-05-29 | 2003-12-04 | Mercian Corporation | Nouvelles substances physiologiquement actives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003501423A (ja) | 1999-06-03 | 2003-01-14 | アメリカ合衆国 | マイコラクトンおよび関連化合物、組成物、ならびに使用方法 |
WO2002012533A2 (en) | 2000-08-03 | 2002-02-14 | Kosan Biosciences, Inc. | Fermentation and purification of mycolactones |
TWI233361B (en) | 2001-04-13 | 2005-06-01 | Gen Hospital Corp | Methods of preventing UVB-induced skin damage |
WO2004011661A1 (ja) * | 2002-07-31 | 2004-02-05 | Mercian Corporation | 新規生理活性物質 |
CN102010403A (zh) | 2005-10-13 | 2011-04-13 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
-
2003
- 2003-11-27 RU RU2005120390/13A patent/RU2330069C2/ru not_active IP Right Cessation
- 2003-11-27 US US10/532,412 patent/US7745198B2/en not_active Expired - Fee Related
- 2003-11-27 CA CA002507641A patent/CA2507641A1/en not_active Abandoned
- 2003-11-27 AU AU2003284469A patent/AU2003284469B2/en not_active Ceased
- 2003-11-27 KR KR1020057009524A patent/KR20050086873A/ko not_active Application Discontinuation
- 2003-11-27 NZ NZ540103A patent/NZ540103A/en unknown
- 2003-11-27 JP JP2004556846A patent/JP4439401B2/ja not_active Expired - Fee Related
- 2003-11-27 BR BR0316746-1A patent/BR0316746A/pt not_active IP Right Cessation
- 2003-11-27 CN CNA2003801044327A patent/CN1717493A/zh active Pending
- 2003-11-27 EP EP03775924A patent/EP1580278A4/en not_active Withdrawn
- 2003-11-27 MX MXPA05005672A patent/MXPA05005672A/es active IP Right Grant
- 2003-11-27 WO PCT/JP2003/015170 patent/WO2004050890A1/ja active Application Filing
-
2005
- 2005-05-27 NO NO20052568A patent/NO20052568L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04352783A (ja) * | 1991-05-27 | 1992-12-07 | Taisho Pharmaceut Co Ltd | 12員環マクロライド系化合物 |
WO2002060890A1 (fr) * | 2001-02-01 | 2002-08-08 | Mercian Corporation | Nouvelles substances physiologiquement actives |
WO2003099813A1 (fr) * | 2002-05-29 | 2003-12-04 | Mercian Corporation | Nouvelles substances physiologiquement actives |
Non-Patent Citations (1)
Title |
---|
See also references of EP1580278A4 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7932083B2 (en) | 2003-11-27 | 2011-04-26 | Mercian Corporation | DNA participating in hydroxylation of macrolide compound |
WO2005052152A1 (ja) * | 2003-11-27 | 2005-06-09 | Mercian Corporation | マクロライド系化合物の水酸化に関与するdna |
EP1770165A1 (en) * | 2004-07-20 | 2007-04-04 | Eisai R&D Management Co., Ltd. | Dna coding for polypeptide participating in biosynthesis of pladienolide |
US8008049B2 (en) | 2004-07-20 | 2011-08-30 | Eisai R&D Management Co., Ltd. | DNA coding for polypeptide participating in biosynthesis of pladienolide |
EP1770165B1 (en) * | 2004-07-20 | 2011-12-21 | Eisai R&D Management Co., Ltd. | Dna coding for polypeptide participating in biosynthesis of pladienolide |
WO2006126723A1 (ja) * | 2005-05-26 | 2006-11-30 | Eisai R & D Management Co., Ltd. | 遺伝子組換え微生物およびそれらの微生物を用いるマクロライド系化合物の製造方法 |
WO2007043621A1 (ja) * | 2005-10-13 | 2007-04-19 | Eisai R & D Management Co., Ltd. | プラジエノライド b及びプラジエノライド dの全合成方法 |
US7816401B2 (en) | 2005-10-13 | 2010-10-19 | Eisai R&D Management Co., Ltd. | Process for total synthesis of pladienolide B and pladienolide D |
US7884128B2 (en) | 2005-10-13 | 2011-02-08 | Eisai R&D Management Co., Ltd. | Process for total synthesis of pladienolide B and pladienolide D |
EP3514154A1 (en) | 2014-05-15 | 2019-07-24 | Eisai R&D Management Co., Ltd. | Pladienolide pyridine compounds and methods of use |
WO2015175594A1 (en) | 2014-05-15 | 2015-11-19 | Eisai R&D Management Co., Ltd. | Pladienolide pyridine compounds and methods of use |
WO2017040526A2 (en) | 2015-09-01 | 2017-03-09 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
US10889866B2 (en) | 2015-09-01 | 2021-01-12 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic SF3B1 mutants |
EP3910073A1 (en) | 2015-09-01 | 2021-11-17 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
US11761045B2 (en) | 2015-09-01 | 2023-09-19 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic SF3B1 mutants |
WO2017087667A1 (en) | 2015-11-18 | 2017-05-26 | Eisai R&D Management Co., Ltd. | A solid state form of pladienolide pyridine compounds and methods of use |
WO2018170129A1 (en) | 2017-03-15 | 2018-09-20 | Eisai Co., Ltd | Spliceosome mutations and uses thereof |
WO2019089641A1 (en) | 2017-10-31 | 2019-05-09 | Eisai R&D Management Co., Ltd. | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use |
WO2019199667A2 (en) | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
WO2019200100A1 (en) | 2018-04-12 | 2019-10-17 | Andrew Cook | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
WO2019232433A2 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
WO2022098712A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
AU2003284469A1 (en) | 2004-06-23 |
US20060141589A1 (en) | 2006-06-29 |
NO20052568D0 (no) | 2005-05-27 |
NZ540103A (en) | 2007-05-31 |
JP4439401B2 (ja) | 2010-03-24 |
MXPA05005672A (es) | 2005-08-16 |
CN1717493A (zh) | 2006-01-04 |
CA2507641A1 (en) | 2004-06-17 |
JPWO2004050890A1 (ja) | 2006-03-30 |
BR0316746A (pt) | 2005-10-18 |
US7745198B2 (en) | 2010-06-29 |
KR20050086873A (ko) | 2005-08-30 |
EP1580278A4 (en) | 2010-08-25 |
RU2005120390A (ru) | 2006-01-27 |
EP1580278A1 (en) | 2005-09-28 |
AU2003284469B2 (en) | 2008-02-21 |
RU2330069C2 (ru) | 2008-07-27 |
NO20052568L (no) | 2005-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004050890A1 (ja) | マクロライド系化合物の製造方法 | |
CZ2002127A3 (cs) | Mikrobiální způsob výroby pravastatinu | |
JP6181972B2 (ja) | 芳香族化合物の製造方法 | |
JP4521145B2 (ja) | 抗生物質カプラザマイシン類およびその製造法 | |
JP5826406B2 (ja) | ストレプトマイセス、抗腫瘍化合物スピロインディマイシン(Spiro−Indimycin)A−D、その製造方法及び使用、並びに、該スピロインディマイシンを含む抗腫瘍剤及び薬物 | |
KR100433888B1 (ko) | HMG-CoA 환원효소 저해제의 제조법 | |
JP4160149B2 (ja) | 新規fo−6979物質およびその製造法 | |
JP3957053B2 (ja) | 新規な微生物及びプラバスタチンの製造方法 | |
WO2002074792A1 (fr) | Substances fo-6979 et procede de production de ces dernieres | |
JP2006314248A (ja) | トリテルペン誘導体の製造方法 | |
JP4439079B2 (ja) | プラバスタチンの製造方法 | |
JP4449015B2 (ja) | シクロスポリン誘導体の製造方法 | |
JP3796539B2 (ja) | グリセロ糖脂質の製造方法及びそれに用いる微生物 | |
KR100386197B1 (ko) | 올레아미드를 생산하는 스트렙토미세스 속 신균주 및 그균주로부터 올레아미드를 생산하는 방법 | |
JPH0625277A (ja) | 新規テストステロン−5α−レダクターゼ阻害物質SNA−4606産生菌、新規テストステロン−5α−レダクターゼ阻害物質SNA−4606及びその製造法 | |
WO1999024439A1 (fr) | Nouvelle substance ft-0554 et procede de fabrication | |
JPH08196288A (ja) | 長鎖脂肪酸の製造法 | |
JPH0378106B2 (ja) | ||
EP2619315A2 (en) | A microbial method for the biotransformation of colchicinoid compounds | |
JPWO2007097010A1 (ja) | Fki−2342物質およびその製造法 | |
JP2005278525A (ja) | 芳香族化合物の製造方法 | |
JPH0378104B2 (ja) | ||
JPH05207894A (ja) | マクロライド系抗生物質の製造法 | |
JPH08182496A (ja) | Fo−2942物質およびその製造法 | |
JPH0378108B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004556846 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 168010 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2006141589 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10532412 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500818 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 540103 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003284469 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003775924 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/005672 Country of ref document: MX Ref document number: 1020057009524 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2507641 Country of ref document: CA Ref document number: 20038A44327 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005120390 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1742/DELNP/2005 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057009524 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003775924 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0316746 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10532412 Country of ref document: US |